Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes

Leukemia

Volumn 10, Issue 9, 1996, Pages 1531-1533

  Munker, R ^a,b   Midis, G ^a   Owen Schaub, L ^a   Andreff, M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Myeloid leukemia; Soluble CD95

Indexed keywords

FAS ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; SEPTICEMIA;

EID: 0029784136     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76: 959-962.
2. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down-regulated with the receptor for tumor necrosis factor. J Exp Med 1989; 169: 1747-1756.
3. Trauth BC et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-305.
4. Alderson MR et al. Fas-ligand mediates activation-induced death in human T lymphocytes. J Exp Med 1995; 181: 71-77.
5. Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol 1994; 57: 129-144.
6. Munker R et al. Expression of the Fas antigen on primary human leukemia cells. Ann Hematol 1995; 70: 15-17.
7. Munker R, Andreeff M. Induction of suicide (CD95/FAS), activation and adhesion molecules on blast cells of acute myelogenous leukemias by TNF-α and IFN-γ. (submitted).
8. Owen-Schaub L et al. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol 1992; 140: 197-205.
9. Watson ML et al. Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med 1992; 176: 1645-1656.
10. Sobel ES, Kakkanaiah VN, Cohen PL, Eisenberg RA. Correction of gld autoimmunity by co-infusion of normal bone marrow suggests that gld is a mutation of the Fas ligand gene. Int Immunity 1993; 5: 1275-1289.
11. Cheng J et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-1762.
12. Cascino I et al. Three functional soluble forms of the human apoptosis-inducing fas molecule are produced by alternative splicing. J Immunol 1995; 154: 2706-2713.
13. Knipping E, Debatin K-M, Stricker K, Heilig B, Eder A, Krammer PH. Identification of soluble APO-1 in supernatants of human B-and T-cell leukemias. Blood 1995; 85: 1562-1569.
14. Owen-Schaub LB et al. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett 1995; 94: 1-8.
15. Estrov Z, Kurzrock R, Talpaz M. Cytokines and their receptors in myeloid disorders. Semin Hematol 1995; 32: 220-231.
16. Carter A, Haddad N, Draxler I, Tatarsky I. Effects of soluble interleukin-1 receptor and tumor-necrosis factor receptor, respectively, on the IL-1- and TNF-a-induced DNA synthesis of acute myeloblastic leukemia blasts in vitro. Eur J Haematol 1994; 53: 38-45.